Moreover, treatment with an FGF receptor 4 (FGFR4) inhibitor, BLU9931, to block FGF19 function (64) recapitulates the effects of HMGA1 or FGF19 silencing, decreasing tumor growth and stroma formation in orthotopic models. Here, HMGA1 is linked to neoplasm.